OncoMatch/Clinical Trials/NCT06917092
QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer
Is NCT06917092 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies QL1706 combined with chemotherapy ± Bevacizumab for endometrial adenocarcinoma.
Treatment: QL1706 combined with chemotherapy ± Bevacizumab — This is a prospective, single-arm, multicenter Phase II study evaluating the efficacy and safety of QL1706 combined with chemotherapy in patients with advanced recurrent or metastatic endometrial cancer who progressed after prior anti-PD-1/L1 therapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Endometrial Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: anti-PD-1 therapy
Patients must have received prior anti-PD-1/L1 monoclonal antibody (mAb) therapy with a progression-free survival (PFS) of ≥6 months
Cannot have received: PD-1/CTLA-4 dual-target immunotherapy
Previous treatment with PD-1/CTLA-4 dual-target immunotherapy
Cannot have received: immune checkpoint agonist (ICOS, CD40, CD137, GITR, OX40 antibodies)
immune checkpoint agonists (e.g., ICOS, CD40, CD137, GITR, OX40 antibodies, etc.)
Cannot have received: immune cell therapy
immune cell therapy
Cannot have received: anti-PD-1/PD-L1 antibody
Exception: discontinuation due to related toxicity
Discontinuation of anti-PD-1/PD-L1 antibody therapy due to related toxicity
Lab requirements
Blood counts
Laboratory tests during the screening period must demonstrate adequate organ function.
Kidney function
Laboratory tests during the screening period must demonstrate adequate organ function.
Liver function
Laboratory tests during the screening period must demonstrate adequate organ function.
Laboratory tests during the screening period must demonstrate adequate organ function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06917092 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior PD-1/CTLA-4 dual-target immunotherapy, immune checkpoint agonist, immune cell therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages